Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Short Interest Up 93.6% in November

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) was the recipient of a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 1,500,000 shares, a growth of 93.6% from the November 15th total of 774,700 shares. Based on an average daily volume of 16,110,000 shares, the short-interest ratio is currently 0.1 days. Approximately 6.7% of the company’s shares are short sold.

Insider Transactions at Tevogen Bio

In related news, insider Neal Flomenberg sold 1,078,600 shares of Tevogen Bio stock in a transaction dated Thursday, October 17th. The shares were sold at an average price of $1.62, for a total transaction of $1,747,332.00. Following the completion of the transaction, the insider now directly owns 4,254,302 shares of the company’s stock, valued at $6,891,969.24. This trade represents a 20.23 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 56.60% of the company’s stock.

Institutional Investors Weigh In On Tevogen Bio

An institutional investor recently bought a new position in Tevogen Bio stock. HGC Investment Management Inc. acquired a new stake in shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 223,077 shares of the company’s stock, valued at approximately $82,000. HGC Investment Management Inc. owned about 0.13% of Tevogen Bio as of its most recent filing with the SEC.

Tevogen Bio Price Performance

Shares of TVGN stock traded down $0.01 during trading hours on Friday, hitting $1.00. 850,593 shares of the company’s stock traded hands, compared to its average volume of 4,787,343. The stock’s fifty day simple moving average is $1.45 and its two-hundred day simple moving average is $0.91. Tevogen Bio has a 12-month low of $0.26 and a 12-month high of $21.09.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.